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-Type Natriuretic Peptides and
chocardiographic Measures of
ardiac Structure and Function
ichard W. Troughton, MB, CHB, PHD, FRACP,
. Mark Richards, MD, PHD, DSC, FRACP
hristchurch, New Zealand
chocardiography and the B-type natriuretic peptides (BNPs) provide powerful incremental assessment of
ardiac function, clinical status, and outcome across the spectrum of cardiac disease. There is strong
vidence to support their integrated use in the diagnosis and management of cardiovascular disease.
mino-terminal pro-B-type natriuretic peptide (NT-proBNP) or BNP may guide more effective use of
chocardiography in screening for asymptomatic left ventricular dysfunction; Doppler echocardiography
mproves the accuracy of heart failure diagnosis in the setting of intermediate BNP or NT-proBNP levels.
ombined assessment of peptides and echocardiography provides more powerful stratification of risk
cross all stagesof heart failure, and integrateduseofboth testsmay identify subjectswith valvular disease
t greatest risk for progression andguidedecision-making for timely intervention. (J AmColl Cardiol Img
009;2:216–25) © 2009 by the American College of Cardiology FoundationB
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d Aince their discovery and characterization,
-type natriuretic peptides have become firmly
stablished as biomarkers for heart failure diag-
osis and for prognosis across the spectrum of
ardiovascular disease (1–3). The relationship be-
ween the B-type peptides and echocardiographic
easures of cardiac structure and function has
een widely explored. Peptide measurements
rovide information complementary or incre-
ental to echocardiography for assessment of
ardiac function, clinical status, and outcome.We
eview these data and consider the potential
linical applications of echocardiography inte-
rated with B-type natriuretic peptide testing.
rom the University Department of Medicine, University of Ota
roughton has received honoraria from Roche Diagnostics as part
eceived honoraria and research grants from Roche Diagnostics an
nverness/Biosite.anuscript received December 4, 2008, accepted December 9, 2008.-type Natriuretic Peptides
he natriuretic peptide family includes atrial,
-type (BNP), C-type natriuretic peptide,
nd urodilatin. BNP is secreted primarily by
trial and ventricular cardiomyocytes and—
ike atrial natriuretic peptide—has vasodila-
or, lusitropic, and natriuretic actions; it also
nhibits cardiac sympathetic traffic, renin-
ngiotensin-aldosterone activity, and cardiac
brosis (3).
The BNP gene encodes pre-pro-BNP, a
34-amino acid (aa) molecule from which
NP signal peptide is cleaved to produce
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217roBNP (amino acids 1 to 108) (4). ProBNP and
ts two cleavage products, the inactive amino-
erminal pro-B-type natriuretic peptide (NT-
roBNP) (aa 1 to 76) and the bioactive molecule
NP (aa 77 to 108) (Fig. 1) are all present in the
irculation. Although secretion of BNP and NT-
roBNP is equimolar, BNP is actively cleared
hrough natriuretic peptide C-receptors and by
eutral endopeptidase, resulting in significantly
ower plasma levels and a shorter half-life (21
in) than NT-proBNP (70 min), for which
learance mechanisms beyond renal filtering are
ess certain. Further processing of proBNP, NT-
roBNP, and BNP within the circulation pro-
uces truncated forms presumably variably recog-
ized by immunoassays and possessing variable
ioactivity (5). This appears to have little impact
n clinical application of current well-validated
mmunoassays for BNP and NT-proBNP (5).
BNP is not stored but is synthesized and
ecreted constitutively in response to cardiomyo-
yte stretch (4). Increased ventricular or atrial
all stress, reflecting volume or pressure over-
oad, is the primary driver of myocyte stretch-
ediated secretion, but ischemia, neurohor-
ones, and cytokines also stimulate or modify
NP gene expression (4).
lasma levels of B-type natriuretic peptides.
alidated commercial assays are available for
NP and NT-proBNP (6). Each assay has dif-
erent performance characteristics and recognizes
ifferent epitopes on the BNP or NT-proBNP
olecule. Although there is generally strong
orrelation between assays, absolute peptide val-
es may vary considerably, so clinicians should
now the reference range and performance char-
cteristics of their local assay (6,7).
Plasma levels of BNP and NT-proBNP in-
rease with age and are lower in men than in
omen (8). Levels are inversely related to body
ass index and lean mass (9) and increase with
orsening glomerular filtration rate (10). Even in
table subjects, peptide levels vary with repeat
esting as a consequence of assay characteristics
nd biological variation (11). Relative variation is
reater in normal subjects, in whom absolute
evels are low. In disease states, absolute levels are
igher and relative variation is lower. In stable
eart failure subjects, changes of more than 23%
or NT-proBNP or 43% for BNP are likely to
ndicate a change beyond that due to background
iological variation (11). sNP and Echocardiographic Indexes of
ardiac Function
iven synthesis primarily by cardiomyocytes, it is
ot surprising that the greatest secretion of B-type
eptides is from the left ventricle (LV). BNP and
T-proBNP levels correlate positively with LV
imensions, volumes, and mass in a variety of
ettings and populations and are inversely related to
V ejection fraction (LVEF) (3,12–15). Peptide
evels are higher with left ventricular hypertrophy
LVH) (14) and are higher still in subjects with
VH and clinical heart failure.(16)
iastolic function. The strongest correlations have
een reported for BNP with LV diastolic wall stress
onsistent with stretch-mediated BNP secretion
Fig. 2) (15). BNP levels increase with
reater severity of overall diastolic dys-
unction, independent of LVEF, age, sex,
ody mass index, and renal function, and
he highest levels are seen in subjects with
estrictive filling patterns (Fig. 3) (17–19).
eptide levels correlate with indexes of
lling pressure—including transmitral
arly filling velocity (E) and its ratio to
arly diastolic annular velocity (E/Ea)—as
ell as with indexes of compliance and
yocardial relaxation (18,19). In subjects
ith normal LVEF, elevated NT-
roBNP (600 pg/ml) or BNP (100
g/ml) are the strongest independent pre-
ictors of severe diastolic dysfunction; low
eptide levels (140 pg/ml) exhibit very
igh negative predictive value (90%) for
iastolic dysfunction (19).
BNP and NT-proBNP levels also re-
ect left atrial size, correlating positively
ith left atrial volume, particularly in the
eneral population and in patients with heart failure
ith preserved systolic function (13,20,21). In
cutely decompensated heart failure or in subjects
ith advanced systolic heart failure, the relationship
etween left atrial volume and BNP appears dimin-
shed, possibly reflecting proportionately greater
eptide secretion from the left and right ventricles
n this context.
ight ventricle. The right ventricle (RV) contributes
o plasma levels of BNP or NT-proBNP, with
ither normal or impaired LVEF. Levels of both
eptides correlate with measures of RV size and
unction, increasing with greater dilatation and
ystolic dysfunction, and with increasing RV pres-
A B B
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218etection of Elevated Left Ventricular
illing Pressures
lasma levels of the B-type peptides reflect mea-
urements of LV filling pressure, but the relation-
hip is often modest and dependent on clinical
B-Type Natriuretic Peptide Molecular Forms and Processing
natriuretic peptide (proBNP) is synthesized primarily within cardi-
and is largely cleaved to form bioactive BNP and the inert
lecule amino-terminal proBNP (NT-proBNP), the major circulating
her processing within the circulation produces truncated forms of
des that can be identiﬁed in plasma. Modiﬁed with permission
et al (5).
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g and B-type natriuretic peptide (BNP) data from 160 subjects
ic heart failure demonstrating that BNP levels correlate with
lar function including: (A) ejection fraction (EF), (B) end diastolic
tolic wall stress (SWS), and (D) end diastolic wall stress (EDWS).p
on from Iwanaga et al. (15).ontext (23). In patients undergoing routine coro-
ary angiography (24), BNP and/or NT-proBNP
orrelate strongly with LV end diastolic pressure
LVEDP) and exhibit modest accuracy for detec-
ion of raised LVEDP (23,24). Smaller studies in
ubjects with stable systolic dysfunction demon-
trate similar strong correlations between BNP or
T-proBNP and either LVEDP or pulmonary
apillary wedge pressure (PCWP) (25,26). In this
ontext, peptide levels are elevated and exhibit good
pecificity but reduced sensitivity and overall accu-
acy for detection of elevated filling pressures (25).
hen LV ejection fraction is preserved but dia-
tolic function is impaired, the correlation between
NP or NT-proBNP and invasively measured fill-
ng pressures is weaker (r  0.45), but negative
redictive values (90%) for elevated LVEDP
emain high (19). In acute decompensated heart
ailure (ADHF), where background BNP or NT-
roBNP levels are significantly elevated, the corre-
ation between peptide levels and filling pressure is
eaker, especially in advanced heart failure or
nselected intensive care patients (23,27). Changes
n peptide levels during therapy for ADHF reflect
linical and hemodynamic changes, but peak pep-
ide changes lag behind the latter (27,28).
The modest relationship between NT-proBNP
r BNP and LV filling pressures is consistent with
he complexity of factors influencing secretion and
learance. In addition to the effects of age, sex, renal
unction, and neurohormonal/cytokine status, se-
retion from the RV and the left atrium contribute
o absolute peptide levels. Left ventricular geometry
s also important, with dilated ventricles secreting
ore peptide for a given filling pressure due to
reater wall stress and chamber mass (15,18).
A single value for BNP or NT-proBNP is
herefore unlikely to provide reliable estimation of
lling pressures across individuals, although very
ow levels retain strong negative predictive values
or an elevated filling pressure in most settings (23).
ithin individuals, however, changes in BNP may
eflect changes in filling pressure, as has been
emonstrated in subjects with implantable moni-
oring devices, where serial BNP measurements
orrelate significantly with ambulatory device-based
stimates of filling pressure (29).
In contrast, accurate estimation of LV filling
ressures by Doppler echocardiography has been
idely validated. Transmitral and pulmonary ve-
ous filling indexes and more particularly, the E/Ea
atio, are now established as markers of fillingFigure 1.
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219road range of clinical settings (30–32). There have
een few comparative studies of echocardiography
ith BNP, however Dokainish et al. (27) compared
alidated Doppler echocardiographic indexes with
NP for detection of PCWP 15mm Hg in
atients admitted to the intensive care unit. In
ubjects with established cardiac disease, a BNP
evel 400 pg/ml demonstrated similar sensitivity
91%) but poorer specificity (51% vs. 91%) and
verall accuracy than Doppler indexes such as E/Ea
or detection of a PCWP 15 mm Hg. However,
n subjects without cardiac disease, BNP proved
ore sensitive (81% vs. 74%) and specific (83% vs.
2%) than Doppler indexes (27). These findings
ndicate that in subjects with known cardiac disease,
oppler echocardiography provides superior esti-
ation of elevated filling pressures. Where there is
o history of cardiac disease, peptide measurement
ay be a preferred initial strategy for detecting
levated filling pressure.
etection of Left Ventricular Systolic and
iastolic Dysfunction
he accuracy of BNP or NT-proBNP in screening
or LV structural and functional abnormalities has
een tested in community, hospital, and high-risk
opulations and appears to depend on the abnor-
ality in question and its prevalence within that
opulation (3,13,20,33–35).
In selected subjects referred for echocardiogra-
hy, BNP has good sensitivity and specificity for
etecting systolic (LVEF 40% to 50%) or dia-
Figure 3. B-Type Natriuretic Peptide and Left Ventricular Diasto
(A) Plasma B-type natriuretic peptide (BNP) levels (pg/ml) are strong
Doppler echocardiography. (B) Gradation of BNP levels according to
higher in clinically decompensated heart failure. Adapted with permtolic dysfunction. Low peptide levels have high begative predictive value; specificity and positive
redictive values increase when the prevalence of
V dysfunction is higher (17,36). Maisel et al. (36)
emonstrated that a BNP level of 75 pg/ml had
n overall accuracy of 90% for detecting either
ystolic (LVEF 50%) or diastolic dysfunction
impaired relaxation pattern or worse on transmitral
lling). BNP levels did not differentiate systolic
rom primary diastolic dysfunction with preserved
VEF. Lubien et al. (17) assessed 294 patients with
ormal systolic function (LVEF50%) referred for
chocardiography. BNP levels rose with increasing
iastolic dysfunction and were higher still if clinical
eart failure was present (Fig. 3). A BNP level of 65
g/ml detected any diastolic dysfunction in this
ontext with a sensitivity of 85%, specificity of 83%,
nd overall accuracy of 84%. Accuracy was greater
hen only restrictive filling was considered (17).
ommunity screening. In community settings, up to
ne-half of all patients with LV dysfunction may be
linically undetected (37). Several studies have as-
essed screening of the general population with
NP or NT-proBNP to detect systolic dysfunction
LVEF 50%), increased LV mass, or diastolic
ysfunction graded on the basis of transmitral
lling as moderate (pseudonormal) or severe (re-
trictive) (33–35,38,39). The prevalence of LV
ysfunction in each study was low (6%), but these
tudies consistently demonstrate a high negative
redictive value (93% to 99%) when BNP or NT-
roBNP levels are low; values for specificity and
verall accuracy are lower (33,35). The lesser accu-
acy of detection of asymptomatic LV dysfunction
unction
elated to overall left ventricular diastolic function assessed by
stolic stage is seen regardless of clinical status, but levels are
on from Lubien et al. (17). CHF  congestive heart failure.lic F
ly r
diay NT-proBNP and BNP in the community setting
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220ay reflect confounding from noncardiac influ-
nces, including age, sex, and renal function, in the
etting of generally low peptide levels and a low
revalence of LV dysfunction. The effect of body
ass on peptide levels may add to background noise
hat reduces the utility of peptide screening, unlike
n heart failure diagnosis, in which the accuracy of
hreshold peptide cut-points appears less affected by
ody mass (3,9). The Framingham study group
ound that use of a single sex-adjusted BNP level
id not significantly improve detection of LV sys-
olic dysfunction (diastolic function was not con-
idered) or LVH over standard clinical and electro-
ardiographic parameters (35). In subjects from
lmsted County, although very low levels of BNP
xcluded significant LV dysfunction, unadjusted
evels appeared suboptimal for routine screening
f the general population, with confirmatory
chocardiography necessary in up to 40% of the
tudy population and up to 60% of cases missed
hen a single unadjusted BNP cut-point value
as applied (33). The same group compared
T-proBNP to BNP in 1,869 community sub-
ects and found that use of age- and sex-adjusted
ut-point factors improved accuracy, with sensi-
ivity and specificity between 90% and 100% for
T-proBNP in detecting LVEF 40% (13).
oth NT-proBNP and BNP were less robust
hen screening for diastolic dysfunction, alone or
n combination with systolic dysfunction.
Although portable echocardiography may pro-
ide a more cost-effective approach to screening for
V dysfunction (40,41), integrated use of NT-
roBNP using age- and sex-adjusted cut-points
ould provide helpful screening for systolic dysfunc-
ion, but not for isolated diastolic dysfunction
20,42). Importantly, BNP and NT-proBNP may
unction best in combination with other tests.
ombining BNP with electrocardiogram or clinical
eatures increases the positive predictive value and
verall accuracy for detection of LV dysfunction
43). Several studies indicate that screening with
NP or NT-proBNP in combination with clinical
arameters is cost-effective in reducing the number
f formal echocardiographic studies needed to iden-
ify LV dysfunction (44). BNP and NT-proBNP
ay function better as a marker of “cardio-renal
ysfunction” rather than specifically for LV dys-
unction (20). In this context, peptide values below
he 97.5th percentile for the normal population,
ave high negative predictive value, essentially rul-
ng out cardio-renal abnormalities in asymptomatic
ubjects (45). wiagnosis of Heart Failure
he prompt and accurate diagnosis of heart failure
acilitates decision making and management in
rimary care and in the emergency room (3,46,47).
owever, early diagnosis remains a significant chal-
enge in these settings, with initial diagnoses based
n clinical assessment often being incorrect (46,47).
NP or NT-proBNP levels are elevated in patients
ith ADHF, and multiple studies have demon-
trated the value of BNP or NT-proBNP for
iagnosis of acute heart failure, regardless of LVEF
46,48,49). In an acutely dyspneic patient, low
eptide levels (100 pg/ml for BNP [49], 300
g/ml for NT-proBNP [48]) rule out ADHF with
negative predictive value of 95%; very high
eptide levels can achieve positive predictive values
85% for ADHF (48). In many of these studies,
chocardiography was included in the gold standard
ssessment of ADHF diagnosis. Smaller studies
omparing echocardiography with peptide methods
how that BNP has similar accuracy to any single
chocardiographic index (such as E/Ea) for diagno-
is of heart failure; comprehensive Doppler echo-
ardiography provides improved specificity (50–
2). Comprehensive echocardiography provides a
articular advantage when BNP or NT-proBNP
evels fall in the intermediate or “grey” zone. For
xample, a restrictive transmitral Doppler pattern
ccurately differentiates acute heart failure from
oncardiac causes of acute dyspnea when BNP
evels fall between 100 and 500 pg/ml (Fig. 4)
50,51). Integrated use of peptide measurement
ollowed by targeted Doppler echocardiography
ould therefore improve the accuracy of early heart
ailure diagnosis for up to 30% of acutely dyspneic
atients who have intermediate peptide levels at
resentation (Fig, 5).
BNP or NT-proBNP levels are higher in heart
ailure with impaired LV systolic function than when
VEF is preserved, consistent with greater wall stress
n the former (15,49). However, peptide levels have
imited accuracy in differentiating these two entities
nd cannot replace echocardiography (49).
onitoring of Heart Failure
otwithstanding the biological variation seen with
epeat peptide measurements, there is growing ev-
dence that serial measurements of BNP or NT-
roBNP may be useful for monitoring clinical
tatus and guiding therapy in heart failure (53,54).
he greatest benefits are seen in younger patients
ith systolic heart failure, in whom reductions in
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221ortality and heart failure events have been dem-
nstrated with peptide-guided therapy (53–55).
In contrast, the role of serial imaging in heart
ailure remains unclear and is generally not advo-
ated in stable patients (41). Repeat measurement
f 2-dimensional and Doppler indexes may be
imited by reproducibility and measurement vari-
bility (41). To date, the value of repeat echocar-
iographic imaging has not been tested in a ran-
omized study, and the few studies comparing serial
chocardiographic imaging and peptide measure-
ent suggest the latter may provide more clinically
seful information (56,57). Further studies are
eeded in this area, particularly to assess integrated
se of imaging and peptide monitoring. The con-
ept that threshold changes in peptides levels could
uide more optimal use of serial or repeated echo-
ardiographic during follow-up warrants testing.
ncremental Risk Assessment Using
chocardiography andB-TypeNatriuretic Peptides
chocardiographic indexes of LV systolic and dia-
tolic function are long established prognostic
arkers in subjects with established cardiovascular
isease (58–60). Equally, BNP and NT-proBNP
ave proven to be among the most powerful indepen-
ent markers of heart failure events and mortality
cross the cardiovascular disease spectrum (3).
It is now clear that evaluation of echocardiographic
ndexes in combination with either BNP or NT-
Figure 5. Integrated Use of BNP and Echocardiography for Hea
Algorithm for integrated use of B-type natriuretic peptide (BNP) lev
age stratiﬁed values for amino-terminal pro-B-type natriuretic pepti
use NT-proBNP 450 pg/ml; 50 to 75 years use NT-proBNP 900 pg/mroBNP provides powerful incremental prediction of
he risk of new heart failure events or mortality
61–65). This is true for subjects from the general
opulation (61), those with cardiovascular risk factors
uch as hypertension (65), or after myocardial infarc-
ion (64). Integration of BNP levels and Doppler
Figure 4. Improved Accuracy of Heart Failure Diagnosis Using B
Doppler Echocardiography
Doppler echocardiography facilitates accurate diagnosis of acute de
sated heart failure (ADHF) in subjects with acute dyspnea and inter
values of B-type natriuretic peptide (BNP). Among 163 patients with
dyspnea, ADHF was conﬁrmed by a BNP level 300 pg/ml and acc
excluded by a level 80 pg/ml. Doppler echocardiography allowed
classiﬁcation of 33 of 40 subjects with intermediate BNP levels. Ada
with permission from Logeart et al. (52). CHF  congestive heart fa
ilure Diagnosis
nd echocardiography for diagnosis of acute heart failure. *Use of
NT-proBNP) provides more accurate test performance: 50 yearsNP and
compen-
mediate
acute
urately
accurate
ptedrt Fa
els a
de (l; 75 years use NT-proBNP 1,800 pg/ml (48).
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222ndexes of diastolic function provides powerful incre-
ental prediction in subjects with established heart
ailure, either at the time of hospitalization (62) or in
he community (63). Although abnormalities of either
ndexes of LV function or of a B-type peptide denote
n increased risk of mortality or heart failure, the
ighest risk is seen in subjects with abnormalities of
oth LV function and peptide level (Fig. 6) (61–65).
okainish et al. (62) evaluated 110 subjects hospital-
zed with heart failure and demonstrated that both
NP levels and E/Ea at discharge were independent
redictors of readmission or death. Addition of E/Ea
o BNP levels significantly increased the chi-square
alue of their multivariate model from 17 to 23 and
dentified nearly all adverse events (47 of 54). These
uthors suggested that after heart failure hospitaliza-
ion, an algorithm stratifying patients at discharge by
NP250 pg/ml and then by E/Ea level15 could
e used to identify most of the subsequent risk of
dverse events.
alvular Heart Disease
ssessment of B-type natriuretic peptide levels in
Incremental Risk Stratiﬁcation Using B-Type Natriuretic
vels and Doppler Echocardiography
jects with dyspnea, the lowest risk for cardiovascular hospitaliza-
th was seen in subjects with amino-terminal pro-B-type natri-
tide (NT-proBNP) 400 pg/ml. In subjects with an elevated
, event rates could be stratiﬁed by a ratio of transmitral to mitral
rly diastolic velocity (E/E’) above or below 15. Adapted with per-
m Whalley et al. (63).atients with valvular heart disease can provide Ndditional information that may guide decision-
aking in regard to interventions. Peptide levels
ise with increasing severity of aortic stenosis
66,67). Although correlations with transvalvular
radients or indexes of LV function are modest;
eptide levels are closely related to symptoms and
an assist in their interpretation in this condition.
eptide levels are independent predictors of mor-
ality or heart failure hospitalization in severe aortic
tenosis, with BNP levels 100 pg/ml and NT-
roBNP levels 600 pg/ml, identifying subjects at
igher risk during conservative therapy for moder-
tely severe or severe aortic stenosis (68). Elevated
NP levels also distinguish true from pseudo-
tenosis in low gradient aortic stenosis, with levels
550 pg/ml predicting poor survival after aortic
alve replacement in this context (66).
BNP and NT-proBNP levels also increase with
reater severity of aortic or mitral regurgitation,
eflecting regurgitant volume, LV size and function,
nd symptomatic status (69,70). Peptide levels
dentify higher risk for adverse events in subjects
ith severe aortic regurgitation and preserved LV
unction (71), suggesting that NT-proBNP in com-
ination with echocardiography could refine prog-
ostic assessment and guide decision-making about
iming for intervention.
onclusions
ntegrated use of echocardiography and plasma
-type natriuretic peptide levels provides powerful
ncremental assessment of cardiac function, clinical
tatus, and outcome across the spectrum of cardiac
isease. NT-proBNP or BNP may guide more
ffective use of echocardiography in screening for
symptomatic LV dysfunction. Doppler echocardi-
graphy improves the accuracy of heart failure
iagnosis in the setting of intermediate BNP or
T-proBNP levels. Combined assessment of pep-
ides and echocardiography provides more powerful
tratification of risk across all stages of heart failure.
ntegrated use of both tests may identify subjects
ith valvular disease at greatest risk for progression
nd facilitate timely intervention.
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